Calbiotech breaks into antibody manufacture
Immunotherapy contractor Calbiotech has started work on a dedicated mAb plant intended to broaden its biopharma service offering.
Immunotherapy contractor Calbiotech has started work on a dedicated mAb plant intended to broaden its biopharma service offering.
PharmaCell, the CMO that makes Provenge for Dendreon in Europe, has agreed to buy a facility from TiGenix to add capacity and a manufacturing contract for a second commercial product.
The end of Lonza’s biosimilar joint venture with Teva will not affect manufacturing capacity, the firm says, as it reports a drop in overall revenue for 2013.